trial

Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia

NCTId NCT01176721
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 20 (actual)
Sponsored by cerbomed GmbH
Primary completion 2011-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
20 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Triple
Start
2010-03
Primary completion
2011-07
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
t-VNS verum

Sponsors

cerbomed GmbHLead Sponsor
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbHCollaborator

Sites

2 total
Munich, GermanyGöttingen, Germany

Linked catalysts

1
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of — primary completion2011-07

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE2
Primary Completion Date
2011-07
Status
COMPLETED
relationships
The graph out of here
drug
t-VNS verum
drug
lead_sponsor
cerbomed GmbH
company
collaborator
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
company
indication
Hallucinations
indication
Dementia
indication
Schizophrenia, Disorganized
indication